Review
Open access
Oct 2026
Complement in HER2-Positive Breast Cancer: A Conditionally Protective Mechanism Under Attack
The therapeutic efficacy of anti-HER2 monoclonal antibodies in breast cancer has traditionally been attributed to direct inhibition of signaling and antibody-dependent cellular cytotoxicity (ADCC). Recent evidence, however, has established complement activation through the classical pathway as a possible adjunct mechan...
D. Petkova, Ivaila Kuleva, Zhasmina Stoyanova et al.
· Antibodies · 0 citations